trimetazidine / Generic mfg. - LARVOL DELTA

SYSTEMATIC REVIEW OF PHARMACOLOGIC THERAPIES FOR NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (ACC 2026) - "Cardiac myosin inhibitors (CMIs) lowered pro-brain natriuretic peptide and troponin, improved diastolic indices, and induced modest left ventricular remodeling; aficamten improved functional status in contrast to mavacamten...Renin-angiotensin-aldosterone system (RAAS) agents were largely neutral, but valsartan improved a composite remodeling score in early nHCM. Metabolic modulators were inconsistent - perhexiline and ninerafaxstat showed some benefits, while ranolazine and trimetazidine did not. CMIs show the most consistent efficacy, followed by SGLT2is and cibenzoline; RAAS agents and metabolic modulators provide variable or limited benefit. Further trials are needed to clarify the role of SGLT2is and CMIs in nHCM."

Review • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

Personalized management of angina and heart failure in clinical practice in the Middle East: a narrative review. (PubMed, J Comp Eff Res) - "Clinicians should consider adding newer antianginal agents (long-acting nitrates, ranolazine, trimetazidine, ivabradine) to beta-blockers + calcium-channel blockers based on patient risk factors. In patients with HF with reduced ejection fraction in sinus rhythm and elevated heart rate, ivabradine should be added to maximum tolerated doses of beta-blockers. Adding ivabradine to first-line therapy improves heart rate control and QoL, and reduces HF-related hospitalization and mortality."

Journal • Review • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Myocardial Infarction

Metabolic Adaptation of CD8⁺ T Cells Limits the Efficacy of Fatty Acid Oxidation Inhibition in Type 1 Diabetes. (PubMed, Int J Biol Sci) - "We investigated whether the fatty acid oxidation (FAO) inhibitor trimetazidine (TMZ), one of only three approved drugs directly targeting cellular metabolism, can restrain autoreactive immunity and delay T1D in non-obese diabetic mice (NOD)...The adaptive upregulation of CPT1A demonstrates a novel evasion mechanism to FAO inhibition and underscores the central role of FAO in sustaining pathogenic T cells. Our work highlights metabolic adaptation as a key determinant of autoimmune progression, validating FAO as a therapeutic target in T1D."

Journal • Diabetes • Immunology • Metabolic Disorders • Obesity • Type 1 Diabetes Mellitus • CD4 • CD8 • CPT1A

Jinxinkang Granule Preserves Myocardial Function by Suppressing Cardiac Senescence Through the cGAS-STING Axis in a Pressure Overload Mouse Model of Heart Failure. (PubMed, Cardiovasc Toxicol) - "Animals were randomized into control, model, JXK (low, medium, high dose), or positive control (trimetazidine) groups...Mechanistically, JXK suppressed TAC-induced upregulation of p16, p53, and MMP3, and inhibited cGAS, STING, p-TBK1, and p-IRF3 activation. JXK preserves cardiac function and attenuates remodeling in pressure overload-induced HF, potentially through inhibition of myocardial senescence and suppression of the cGAS-STING pathway."

Journal • Preclinical • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Immunology • MMP3 • STING

Systematic review and meta-analysis of clinical trials on the efficacy and safety of trimetazidine in patients with heart failure (HEART FAILURE 2026) - No abstract available

Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Heart Failure

Inhibiting Fatty Acid Oxidation With a Mitotrope in Heart Failure With Preserved Ejection Fraction. (PubMed, Circulation) - No abstract available

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Trimetazidine is associated with suppression of endoplasmic reticulum stress-mediated NLRP3 inflammasome activation in type 1 diabetes-induced liver damage in rats. (PubMed, Eur J Med Res) - "These results demonstrate a hepatoprotective role for TMZ in T1D-induced liver injury, potentially mediated through suppression of ER stress, inflammation, and caspase-1-dependent pyroptosis."

Journal • Preclinical • Diabetes • Hepatology • Inflammation • Liver Failure • Metabolic Disorders • Type 1 Diabetes Mellitus • CASP1 • ERN1 • IL1B • NLRP3

Evaluation of trimetazidine in alleviating paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled trial. (PubMed, Front Pharmacol) - P1/2 | "Further large-scale studies with longer follow-up are warranted to confirm these findings and explore effects across different chemotherapy regimens. https://clinicaltrials.gov/study/NCT06459193, identifier NCT06459193."

Clinical • Journal • Breast Cancer • Gynecologic Cancers • Oncology • Pain • Solid Tumor • NGF

Trimetazidine modulates angiogenesis, inflammation, and metabolism-related gene expression to promote diabetic foot ulcer healing: a transcriptomic analysis. (PubMed, Pharmacol Rep) - "These results highlight TMZ's potential to modulate gene networks associated with angiogenesis, inflammation, and metabolism. The findings are exploratory and warrant validation in preclinical models to assess their therapeutic relevance."

Journal • Cardiovascular • Diabetes • Inflammation • Metabolic Disorders • GLI2 • PACERR • PTGS2 • SIRT3 • TLR4

Lomerizine M6-An Important Urinary Metabolite in Anti-Doping Control Analysis for Correct Detection of Trimetazidine Abuse in Both Females and Males. (PubMed, Drug Test Anal) - "However, lomerizine M6 concentrations are not always higher than trimetazidine concentrations. Special care should be taken when interpreting trimetazidine concentrations at 1 ng/mL or below."

Journal • CNS Disorders • Migraine • Pain

Carfilzomib-induced sinus bradycardia: A case report and literature review. (PubMed, SAGE Open Med Case Rep) - "The condition was effectively managed following treatment with a combination of trimetazidine and salbutamol. To our knowledge, this is the first reported case of carfilzomib-associated sinus bradycardia, expanding the spectrum of proteasome inhibitors-related cardiotoxicity. This provides inspiration for suspected patients to stop using carfilzomib early and symptomatic treatment can effectively reduce mortality and improve prognosis."

Journal • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Hematological Malignancies • Hypertension • Multiple Myeloma • Oncology

Study on the Mechanism of Trimetazidine Hydrochloride Alleviating Waterlogging Stress in Rapeseed (Brassica napus L.). (PubMed, Physiol Plant) - "Comprehensive analysis showed that TMZ could improve waterlogging tolerance of rapeseed by promoting antioxidant defense and osmotic adjustment, inhibiting fatty acid oxidation, accelerating glycolysis, and promoting photosynthesis efficiency. Various hormones, such as ethylene (ET), abscisic acid (ABA), jasmonic acid (JA), and brassinosteroid (BRs), could regulate this process through mutual synergy or antagonism."

Journal • CAT

Trimetazidine Attenuates Ulcerative Colitis-Linked Extrapyramidal Dysfunction by Mediated Dectin-1/LRRK2/α-Synuclein Autophagy Axis. (PubMed, Microsc Microanal) - "Molecular docking and dynamics confirmed TMZ binding to Dectin-1, LRRK2, and αSyn, through hydrophobic and hydrophilic interactions. These findings suggest a potential molecular basis for the observed associations between the Dectin-1/LRRK2/α-synuclein axis and UC-related motor dysfunction, warranting further experimental validation, establishing TMZ's therapeutic potential for managing colonic inflammation and associated neurological manifestations."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • CLEC7A • IFNG • LAMP2 • LRRK2

Trimetazidine and allopurinol for the prevention of Contrast-associated acute kidney injury in elective percutaneous coronary intervention: a randomized controlled trial. (PubMed, Eur J Clin Pharmacol) - "The TMZ-allopurinol combination showed a favorable but non-significant trend toward reducing CA-AKI, while ACEF and Mehran scores demonstrated limited predictive value. Improved risk-stratification tools and larger studies in higher-risk patients are needed. SGLT2 and DPP-4 inhibitors showed smaller creatinine increases, suggesting possible nephroprotection, but this remains exploratory."

Journal • Acute Kidney Injury • Nephrology • Renal Disease

The myocardial ischemic cascade network and multi-target synergistic interventions: From molecular mechanisms to therapeutic innovations. (PubMed, Biochem Pharmacol) - "Cell death is targeted using ferroptosis inhibitors (e.g., Liproxstatin-1), NLRP3/caspase-1 blockers, and autophagy regulators (e.g., Astragaloside IV). Mitochondrial/metabolic therapies include mitochondrial-targeted drugs (e.g., CsA@PLGA-PEG-SS31), metabolic modulators (Trimetazidine), and neuroendocrine agents (ARNI, SGLT2 inhibitors)...Precision medicine integrates multi-omics and AI for risk stratification, while biomimetic nanocarriers enhance drug delivery. Future therapies should co-target the "energy-death-inflammation" network to advance myocardial ischemia treatment toward systemic repair and improved clinical outcomes."

Journal • Review • Cardiovascular • Gene Therapies • Inflammation • Metabolic Disorders • Myocardial Ischemia • Reperfusion Injury • ALDH2 • NLRP3 • SIRT3

Targeting ferroptosis by trimetazidine and probiotics to attenuate 5-fluorouracil-induced intestinal mucositis in mice. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "The combination also provided additional improvement in intestinal structure (villus height, crypt depth, and enteritis score) compared with each monotherapy group. Either trimetazidine or probiotics alleviated 5-FU-induced intestinal mucositis and might be considered promising candidates for preventing CIM by anti-inflammatory, antioxidant, and mechanisms associated with modulation of ferroptosis-related pathways."

Journal • Preclinical • Gastrointestinal Disorder • Mucositis • Oncology • GPX4 • IL1B • SLC7A11

Kynurenine Pathway Metabolites as Mediators of Exercise-Induced Mood Enhancement, Fatigue Resistance, and Neuroprotection. (PubMed, Int J Mol Sci) - "Furthermore, pharmacological "exercise mimetics" and metabolic modulators, such as PPAR agonists, AMPK activators, NAD+ boosters, meldonium, trimetazidine, and adiponectin receptor agonists, may be promising adjuncts for patients with low exercise capacity or metabolic comorbidities...This perspective consolidates scattered mechanistic and clinical data and outlines a forward-looking therapeutic framework that links exercise and lifestyle, metabolism, and drug discovery. We highlight that re-consideration of our understanding of depression, as a whole-body disorder, should provide new opportunities for precision interventions."

Journal • Review • CNS Disorders • Depression • Fatigue • Immunology • Inflammation • Major Depressive Disorder • Mood Disorders • Psychiatry • FGF21 • IL6 • LEP

Effect of Long Term Trimetazidine Treatment on Final Myocardial Fibrosis for ST Eleviation Myocardial Infarction (clinicaltrials.gov) - P=N/A | N=194 | Completed | Sponsor: Chinese PLA General Hospital

New trial • Cardiovascular • Fibrosis • Immunology • Myocardial Infarction

Trimetazidine Ameliorates Progression of Diabetic Nephropathy by Reducing Serum Creatinine Level in Streptozotocin Induced Diabetic Rats. (PubMed, Mymensingh Med J) - "In TMZ treated group, whereas serum creatinine was significantly (p<0.01) lower when compared with STZ induced nephropathy groups of rats. It may be assumed from the present study that trimetazidine has cytoprotective as well as prevent renal damaged because of its special antioxidant effects, which can delay the onset, severity and progression of nephropathy induced by STZ in rats by reducing serum creatinine level."

Journal • Preclinical • Diabetic Nephropathy • Nephrology • Renal Disease

Mortality differences in coronary patients with breast cancer treated with trimetazidine dihydrochloride: potential therapeutic implications. (PubMed, Cardiooncology) - No abstract available

Journal • Breast Cancer • Oncology • Solid Tumor

Mechanistic insights into trimetazidine's protection against bladder ischemia-reperfusion injury via mirR-211/CHOP modulation and SIRT1/AMPK/PGC1α-mediated mitochondrial biogenesis. (PubMed, Toxicol Appl Pharmacol) - "TMZ exerts strong antioxidant, anti-inflammatory, anti-apoptotic, and cytoprotective effects in bladder I/R injury via modulation of oxidative stress, ER stress, mitochondrial pathways, and the mirR-211/CHOP axis. These findings suggest that TMZ may represent a promising therapeutic candidate for ischemia-associated bladder dysfunction, providing a mechanistic basis for future translational and clinical investigation."

Journal • Cardiovascular • Inflammation • Reperfusion Injury • Urology • AMPK • CASP3 • IL1B • SIRT1 • TNFA

Efficacy and Prognosis of Blinatumomab As a Bridge Therapy for Hematopoietic Stem Cell Transplantation for B-ALL (ASH 2024) - "MRD of the target genes was quantified using a multiparameter Flow cytometry, and the bridged Hematopoietic stem cell transplantation was performed after 7 days of 28 UG of Blinatumoma treatment, it uses dexamethasone to prevent CRS, Levetiracetam to prevent ICAN, and trimetazidine to nourish the myocardium.Methods : Forty-four patients (22 female, 22 male) , with a median age of 36.5(13-60 years) . With a median follow-up of 11 months, 41 patients had 1-year OS and PFS of 77.9% and 76.9% , respectively, and 10 MRD positive patients had 1-year OS and PFS of 66.4% and 65.6% , respectively, the 1-year OS and PFS of 31 MRD negative patients were 82.4% and 82% , respectively. Nine patients died after transplantation, including 9 from severe infection, 2 from GVHD and 3 from relapse.Result : Bridging transplantation after 7 days of continuous use of Blinatumoma has been shown to improve remission rates and long-term survival in patients with B-ALL, particularly in..."

Clinical • Bone Marrow Transplantation • Cardiovascular • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation

Intranasal Liposomal Trimetazidine Nanocarriers Modulate Neuroinflammation and Neurotransmission via the HMGB1/TLR4/NF-κB Pathway in an Experimental Epilepsy Model. (PubMed, Mol Neurobiol) - "These findings demonstrate the potential of intranasal delivery of NTMZ as a novel formulation for managing epilepsy through its improved bioavailability, reduced dose, sustained release, and potent neuroprotective properties. Simultaneously, pharmacological modulation of neuroinflammation and neurotransmitters were observed."

Journal • CNS Disorders • Cognitive Disorders • Epilepsy • Inflammation • Metabolic Disorders • HMGB1 • IL1B • IL6 • TLR4 • TNFA

Early combination therapy with trimetazidine rapidly improves symptoms and quality of life in patients recently diagnosed with stable angina: The COMBINE angina study. (PubMed, Int J Cardiol) - P | "The real-world COMBINE Angina study showed that early initiation of trimetazidine combination therapy can rapidly reduce the burden of stable angina in patients not promptly controlled by a first-line calcium channel blocker or β-blocker."

HEOR • Journal • Cardiovascular • Myocardial Ischemia

Comparative Hepatoprotective Effects of Dapagliflozin and Trimetazidine in Diabetic Rats with Doxorubicin-Induced Liver Injury. (PubMed, Biomedicines) - " Dapagliflozin and trimetazidine each attenuated diabetes- and doxorubicin-related hepatic injury through partly distinct mechanisms, with the combination providing additive but not consistently superior effects. These findings suggest a potential hepatoprotective role for both agents; however, the clinical implications remain uncertain and require confirmation in further mechanistic and translational studies."

Journal • Preclinical • Diabetes • Hepatology • Liver Failure • Metabolic Disorders • Oncology • CASP3 • NFKB1 • TGFB1 • TNFA